SK19398A3 - Allergen-xcd32 fusion proteins - Google Patents

Allergen-xcd32 fusion proteins Download PDF

Info

Publication number: SK19398A3
Authority: SK; Slovakia
Prior art keywords: fusion protein; cells; der; antigen; human
Prior art date: 1995-08-16

Application number

SK193-98A

Other languages

English (en)

Slovak (sk)

Inventor

Geert C Mudde

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-16

Filing date

1996-08-16

Publication date

1998-09-09

1996-08-16 Application filed by Novartis Ag filed Critical Novartis Ag

1998-09-09 Publication of SK19398A3 publication Critical patent/SK19398A3/sk

Links

102000037865 fusion proteins Human genes 0.000 title claims abstract description 58
108020001507 fusion proteins Proteins 0.000 title claims abstract description 58
108091007433 antigens Proteins 0.000 claims abstract description 60
239000000427 antigen Substances 0.000 claims abstract description 59
102000036639 antigens Human genes 0.000 claims abstract description 59
101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims abstract description 46
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims abstract description 46
101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims abstract description 45
210000001744 T-lymphocyte Anatomy 0.000 claims description 38
108090000623 proteins and genes Proteins 0.000 claims description 29
206010020751 Hypersensitivity Diseases 0.000 claims description 22
238000000034 method Methods 0.000 claims description 21
230000007815 allergy Effects 0.000 claims description 19
108020003175 receptors Proteins 0.000 claims description 15
102000005962 receptors Human genes 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 8
208000004262 Food Hypersensitivity Diseases 0.000 claims description 7
235000020932 food allergy Nutrition 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
230000003266 anti-allergic effect Effects 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
238000010382 chemical cross-linking Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000000069 prophylactic effect Effects 0.000 claims description 3
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
206010039085 Rhinitis allergic Diseases 0.000 claims description 2
201000009961 allergic asthma Diseases 0.000 claims description 2
208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
230000000172 allergic effect Effects 0.000 claims description 2
201000010105 allergic rhinitis Diseases 0.000 claims description 2
208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
208000010668 atopic eczema Diseases 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
108010073807 IgG Receptors Proteins 0.000 abstract 2
102000009490 IgG Receptors Human genes 0.000 abstract 2
239000013566 allergen Substances 0.000 description 56
210000003719 b-lymphocyte Anatomy 0.000 description 49
230000030741 antigen processing and presentation Effects 0.000 description 26
210000001616 monocyte Anatomy 0.000 description 23
230000000638 stimulation Effects 0.000 description 22
229960004784 allergens Drugs 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 14
238000005406 washing Methods 0.000 description 14
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
208000026935 allergic disease Diseases 0.000 description 11
238000000576 coating method Methods 0.000 description 11
210000000612 antigen-presenting cell Anatomy 0.000 description 10
239000011248 coating agent Substances 0.000 description 10
230000001404 mediated effect Effects 0.000 description 10
AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical group C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 9
230000003993 interaction Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
230000006698 induction Effects 0.000 description 8
108090000978 Interleukin-4 Proteins 0.000 description 7
231100000673 dose–response relationship Toxicity 0.000 description 7
210000003630 histaminocyte Anatomy 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
108091008875 B cell receptors Proteins 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
241000283707 Capra Species 0.000 description 6
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
230000005867 T cell response Effects 0.000 description 6
238000013459 approach Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
210000004443 dendritic cell Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000028993 immune response Effects 0.000 description 6
238000011534 incubation Methods 0.000 description 6
210000004241 Th2 cell Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000012228 culture supernatant Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
108700027921 interferon tau Proteins 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
235000018185 Betula X alpestris Nutrition 0.000 description 4
235000018212 Betula X uliginosa Nutrition 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
241000238711 Pyroglyphidae Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
229940046533 house dust mites Drugs 0.000 description 4
230000016784 immunoglobulin production Effects 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000002823 phage display Methods 0.000 description 4
230000008884 pinocytosis Effects 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000010600 3H thymidine incorporation assay Methods 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000002109 Argyria Diseases 0.000 description 3
101710117545 C protein Proteins 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000000447 Th1 cell Anatomy 0.000 description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
239000004927 clay Substances 0.000 description 3
239000000428 dust Substances 0.000 description 3
239000012636 effector Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000005185 salting out Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
241001674044 Blattodea Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000006354 HLA-DR Antigens Human genes 0.000 description 2
108010058597 HLA-DR Antigens Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001514 detection method Methods 0.000 description 2
125000002228 disulfide group Chemical group 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
229940046528 grass pollen Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
101150082998 pi gene Proteins 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
238000011158 quantitative evaluation Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
241000143060 Americamysis bahia Species 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001672999 Escura Species 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
206010016946 Food allergy Diseases 0.000 description 1
102000015789 HLA-DP Antigens Human genes 0.000 description 1
108010010378 HLA-DP Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
MQUYPYFPHIPVHJ-MNSWYVGCSA-N Tyr-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)O MQUYPYFPHIPVHJ-MNSWYVGCSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000013575 birch pollen allergen Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
235000020247 cow milk Nutrition 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000013568 food allergen Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Insects & Arthropods (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SK193-98A 1995-08-16 1996-08-16 Allergen-xcd32 fusion proteins SK19398A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9516760.7A GB9516760D0 (en)	1995-08-16	1995-08-16	Organic compounds
PCT/EP1996/003616 WO1997007218A1 (en)	1995-08-16	1996-08-16	Allergen-xcd32 fusion proteins

Publications (1)

Publication Number	Publication Date
SK19398A3 true SK19398A3 (en)	1998-09-09

Family

ID=10779307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK193-98A SK19398A3 (en)	1995-08-16	1996-08-16	Allergen-xcd32 fusion proteins

Country Status (16)

Country	Link
EP (1)	EP0846178A1 (zh)
JP (1)	JPH11513025A (zh)
KR (1)	KR19990036440A (zh)
CN (1)	CN1193353A (zh)
AU (1)	AU6873596A (zh)
BR (1)	BR9610239A (zh)
CA (1)	CA2227795A1 (zh)
CZ (1)	CZ43798A3 (zh)
GB (1)	GB9516760D0 (zh)
HU (1)	HUP9802349A3 (zh)
IL (1)	IL122898A0 (zh)
NO (1)	NO980566L (zh)
PL (1)	PL324897A1 (zh)
SK (1)	SK19398A3 (zh)
TR (1)	TR199800214T1 (zh)
WO (1)	WO1997007218A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
JP2002529048A (ja)	1997-12-02	2002-09-10	メダレツクス・インコーポレーテツド	抗−Ｆｃ受容体結合成分を発現する細胞
EP1221317A1 (en) *	2000-12-28	2002-07-10	SHAN-Beteiligungsgesellschaft m.b.H.	Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
US8025873B2 (en)	2002-06-20	2011-09-27	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
US8007805B2 (en)	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
BG65715B1 (bg) *	2003-09-04	2009-08-31	Чавдар ВАСИЛЕВ	Средство за селективно подтискане на патологични днк - специфични в клетки
BG65954B1 (bg) *	2005-01-05	2010-07-30	Чавдар ВАСИЛЕВ	Средство за селективно подтискане активността на патологични автореактивни в-клетки
EP1829895A1 (en) *	2006-03-03	2007-09-05	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US9636415B2 (en)	2006-03-03	2017-05-02	S-Target Therapeutics Gmbh	Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
KR102107646B1 (ko)	2012-06-15	2020-05-08	이뮤노믹 쎄라퓨틱스, 인크.	알레르기 치료용 핵산
US10434170B2 (en)	2012-07-13	2019-10-08	S-Target Therapeutics Gmbh	Immunoregulatory vaccine
AU2013340899B2 (en) *	2012-11-01	2017-10-05	Veterinaerinstituttet	New fusion proteins for the treatment of allergic diseases
US9005630B2 (en)	2012-11-01	2015-04-14	Veterinaerinstituttet	Fusion proteins for the treatment of allergic diseases
EP2999485B1 (en)	2013-05-21	2018-01-31	Tyg Oncology Ltd.	Gastrin peptide immunogenic composition
CN113186167B (zh) *	2021-04-28	2021-11-30	中国食品药品检定研究院	用于测定抗cd20单克隆抗体药物adcp生物学活性的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994024281A1 (en) *	1993-04-14	1994-10-27	Immulogic Pharmaceutical Corporation	T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2188812A1 (en) *	1994-05-26	1995-12-07	Mark De Boer	New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

1995
- 1995-08-16 GB GBGB9516760.7A patent/GB9516760D0/en active Pending
1996
- 1996-08-16 HU HU9802349A patent/HUP9802349A3/hu unknown
- 1996-08-16 CA CA002227795A patent/CA2227795A1/en not_active Abandoned
- 1996-08-16 AU AU68735/96A patent/AU6873596A/en not_active Abandoned
- 1996-08-16 BR BR9610239A patent/BR9610239A/pt not_active Application Discontinuation
- 1996-08-16 TR TR1998/00214T patent/TR199800214T1/xx unknown
- 1996-08-16 PL PL96324897A patent/PL324897A1/xx unknown
- 1996-08-16 WO PCT/EP1996/003616 patent/WO1997007218A1/en not_active Application Discontinuation
- 1996-08-16 CZ CZ98437A patent/CZ43798A3/cs unknown
- 1996-08-16 KR KR1019980701110A patent/KR19990036440A/ko not_active Application Discontinuation
- 1996-08-16 CN CN96196311A patent/CN1193353A/zh active Pending
- 1996-08-16 SK SK193-98A patent/SK19398A3/sk unknown
- 1996-08-16 IL IL12289896A patent/IL122898A0/xx unknown
- 1996-08-16 EP EP96929263A patent/EP0846178A1/en not_active Withdrawn
- 1996-08-16 JP JP9508953A patent/JPH11513025A/ja active Pending
1998
- 1998-02-10 NO NO980566A patent/NO980566L/no unknown

Also Published As

Publication number	Publication date
CN1193353A (zh)	1998-09-16
MX9801253A (es)	1998-05-31
PL324897A1 (en)	1998-06-22
IL122898A0 (en)	1998-08-16
CZ43798A3 (cs)	1998-06-17
JPH11513025A (ja)	1999-11-09
AU6873596A (en)	1997-03-12
NO980566D0 (no)	1998-02-10
HUP9802349A2 (hu)	1999-01-28
NO980566L (no)	1998-02-10
BR9610239A (pt)	1999-06-15
HUP9802349A3 (en)	1999-04-28
KR19990036440A (ko)	1999-05-25
GB9516760D0 (en)	1995-10-18
WO1997007218A1 (en)	1997-02-27
CA2227795A1 (en)	1997-02-27
EP0846178A1 (en)	1998-06-10
TR199800214T1 (xx)	1998-06-22

Publication	Publication Date	Title
KR100320631B1 (ko)	2002-03-08	항-Fc수용체항체로구성된치료화합물
KR102198189B1 (ko)	2021-01-05	Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
JP3421970B2 (ja)	2003-06-30	ペプチド免疫原
Redpath et al.	1998	The influence of the hinge region length in binding of human IgG to human Fcγ receptors
JP3457962B2 (ja)	2003-10-20	特定Ｆｃεレセプターのための免疫グロブリン変異体
SK19398A3 (en)	1998-09-09	Allergen-xcd32 fusion proteins
Sgroi et al.	1995	Regulation of CD45 engagement by the B-cell receptor CD22.
Vernersson et al.	2002	Generation of therapeutic antibody responses against IgE through vaccination
US20010014328A1 (en)	2001-08-16	Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies
CA2074089C (en)	2001-04-10	Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
WO1989006138A1 (en)	1989-07-13	UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
HU230769B1 (hu)	2018-03-28	Módosított effektor-funkciójú polipeptid-változatok
US5942229A (en)	1999-08-24	Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent
Terness et al.	1995	The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope.
Zhang et al.	2019	A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity
Yu et al.	1999	Immunochemical properties of anti-Galα1–3Gal antibodies after sensitization with xenogeneic tissues
AU734853B2 (en)	2001-06-21	Methods of prolonged suppression of humoral immunity
US5260416A (en)	1993-11-09	Antigenic epitopes present on membrane-bound but not secreted IgE
SAYERS et al.	1999	The structural basis of human IgE–Fc receptor interactions
Pène et al.	1983	Induction of a cross-reactive idiotype dextran-positive antibody response in two IgH-Cb mouse strains treated with anti-J558 cross-reactive idiotype antibodies.
JPH10509948A (ja)	1998-09-29	Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
Laffer et al.	2001	A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcϵRI interaction and reacts with receptor-bound IgE
Wilson et al.	2002	Effector roles of IgE antibodies: targeting allergen to the high affinity IgE receptor for FcRI-dependent signaling and antigen presentation
WO2000050460A1 (en)	2000-08-31	Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
JPH05502854A (ja)	1993-05-20	寛容原性イムノグロブリン―蛋白質結合体